News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
October 2020
-
Media ReleaseNovartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine
-
Media ReleaseNovartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraineResults presented at the Migraine Trust Virtual Symposium highlight long-term benefit of Aimovig Aimovig has the longest duration of safety and efficacy trial data for any anti-CGRP pathway…
September 2020
-
StatementLife Science Companies and the Bill & Melinda Gates Foundation: Joint CommuniqueCommitments to expanded global access for COVID-19 diagnostics, therapeutics, and vaccines.
-
Day of Reflection at Novartis
On this Day of Reflection, Novartis associates are thinking and talking about what it means to be part of a truly diverse and inclusive organization.
-
Media ReleaseNovartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
-
Media ReleaseNovartis US Foundation commits $25M to improve health equity by reducing health disparities in the USBuilding on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on social injustice Commitment to include…
-
Media ReleaseNovartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
-
Media ReleaseNovartis presents data at ACTRIMS-ECTRIMS on the effects of treatment with Mayzent® (siponimod) studied on disability progression and cognitive processing speed in patients with progressing relapsing multiple sclerosisSubgroup post hoc analysis of EXPAND reported that Mayzent reduced the risk of cognitive worsening and improved the chance of cognitive improvement at 6 months versus placebo in patients with…
-
Media ReleaseNovartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosisNew post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and prolonged time to…
August 2020
-
Media ReleaseNovartis PARALLAX data provides further evidence of the potential benefit of Entresto® in patients with HFpEFPARALLAX met one of its co-primary endpoints, showing a significant reduction in NT-proBNP with Entresto (sacubitril/valsartan) compared to individualized medical therapy (IMT) at 12 weeks1; no…
-
Media ReleaseNovartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
-
Media ReleaseNovartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiranPooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164…
Pagination
- ‹ Previous page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- …
- 56
- › Next page